CTOR

Citius Oncology
CTOR

1.26 USD
+0.05
4.13%
At close Updated Nov 26, 4:00 PM EST
Pre-market
After hours
1.33
+0.07
5.56%
1 day
4.13%
5 days
2.44%
1 month
-26.74%
3 months
-36.68%
6 months
41.57%
Year to date
5.88%
1 year
26.52%
5 years
-87.51%
10 years
-87.51%
 

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Healthcare Drug Manufacturers - Specialty & Generic
0
Funds holding %
of 7,476 funds
Explore Fund Trends
0
Analysts bullish %
of 1 analysts
See Analyst Outlook
–
Positive news %
of articles
Check Journalist POV
Price charts implemented using Lightweight Charts™